Mesoblast (ASX:MSB) set the price for its Ryoncil mesenchymal stromal cell therapy as it seeks to launch the product in the coming weeks, according to a Thursday Australian bourse filing.
Ryoncil is a mesenchymal stromal cell therapy approved by the US Food and Drug Administration on Dec. 18, 2024, as the only therapy for pediatric patients aged two months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease.
The firm said its commercial execution is underway, and it is engaging with the top 45 centers representing 80% of pediatric transplants in the US.
Mesoblast plans to further evaluate the immunomodulatory effects of Ryoncil on gastrointestinal inflammation in treating medically refractory pediatric Crohn's disease patients.
The company's shares rose past 2% in recent trading on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。